The introduction of HB 9828 could significantly alter the landscape of vaccine-related liability in the U.S. public health framework. With the removal of liability protection for vaccine manufacturers, the bill may increase the willingness of individuals to pursue civil actions for vaccine-related injuries or deaths. Additionally, it may shift the financial risk associated with vaccine production and distribution, which could have implications for vaccine availability and development processes. This change is particularly noteworthy in the context of ongoing discussions around vaccine safety and efficacy in the wake of the COVID-19 pandemic.
Summary
House Bill 9828, referred to as the 'End the Vaccine Carveout Act', aims to amend the Public Health Service Act by ending the liability shield for vaccine manufacturers. This bill allows individuals who may have suffered health complications due to vaccines to pursue compensation through civil lawsuits. Previously, such claims were directed through a specific compensation program, which limited the rights of individuals to sue vaccine manufacturers directly. By making this change, the bill seeks to provide more legal avenues for addressing grievances related to vaccine administration.
Contention
The bill has sparked debate among legislators and public health advocates. Proponents argue that it creates accountability for vaccine manufacturers, thereby encouraging safer vaccine practices and fostering public confidence in vaccine safety. On the other hand, opponents express concerns that eliminating the liability shield may lead to excessive litigation and discourage pharmaceutical companies from developing new vaccines due to increased financial risk. The tension between public health policy and individual rights regarding vaccine injury claims remains central to the discussions surrounding this legislation.
A bill for an act relating to controlled substances, including certain controlled substances schedules and precursor substances reporting requirements, making penalties applicable, and including effective date provisions. (Formerly HSB 25.) Effective date: 03/28/2025.
A bill for an act relating to controlled substances, including certain controlled substances schedules and precursor substances reporting requirements, making penalties applicable, and including effective date provisions.(Formerly SSB 1080.)